An­oth­er TIG­IT up­date from Ar­cus leaves an­a­lysts read­ing the tea leaves — and the big re­veal is fi­nal­ly near

Once again, any­one who’s look­ing for pos­i­tive sig­nals in Ar­cus’ lat­est slice of TIG­IT da­ta will have to take the biotech’s word for it.

Ar­cus opened its Q1 re­sults with an up­date about its third in­ter­im analy­sis for the ARC-7 study, a Phase II tri­al com­par­ing three dif­fer­ent reg­i­mens: a PD-1 monother­a­py, a TIG­IT plus PD-1 com­bo, as well as a triplet con­tain­ing PD-1, TIG­IT and an A2aR/A2bR an­tag­o­nist. With­out spelling out the num­bers, ex­ecs said “both an­ti-TIG­IT dom­vanal­imab-con­tain­ing arms con­tin­ued to show mean­ing­ful dif­fer­en­ti­a­tion com­pared to the an­ti-PD1 an­ti­body zim­bere­limab alone when giv­en as a treat­ment for first-line metasta­t­ic non-small cell lung can­cer (NSCLC).”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER